ClinicalTrials.gg
RecruitingNCT05733910SIBACIRTUpdated Feb 13, 2025

Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma

An interventional study of simultaneous integrated boost of carbon ions radiation therapy in Carcinoma, Adenoid Cystic and Head and Neck Cancer, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by CNAO National Center of Oncological Hadrontherapy · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The investigators aim at investigating in a prospective clinical trial whether using a Simoultaneous Integrated Boost of carbon ions treatment planning approach, improving the tumor dose conformation while lowering the unintended dose to the low-risk volume, can significantly reduce the probability of toxicity without affecting Local Control.

Read the detailed description

In photon radiotherapy, Simultaneous integrated boost (SIB)-intensity-modulated radiation therapy (IMRT) with slight hypofractionation in the HR-CTV is the current standard of care, being previously largely adopted in clinical practice and within several prospective clinical trials, with similar results in terms of toxicity and oncologic outcome.

Up to now, a simultaneous integrated boost (SIB) approach has not been fully exploited in CIRT so far. The expected benefit of a SIB planning approach in carbon ion treatment is the reduction of toxicity with respect to the sequential (SEQ) approach currently used in CNAO clinical practice, while maintaining the same local control rate. This benefit depends on the potentiality of SIB to better spare normal tissues, further enhancing the intrinsic favourable physical and radiobiological characteristics of the carbon ions.

02

Conditions studied

  • Carcinoma, Adenoid Cystic
  • Head and Neck Cancer

Keywords

  • adenoid cystic carcinoma
  • hadrontherapy
  • carbon ion radiation therapy CIRT
  • head and neck cancer
  • SIB
03

In context

Carcinoma, Adenoid Cystic

86 studies on the registry are indexed under Carcinoma, Adenoid Cystic; 26 are open to participants now.

This study's planned enrollment of 42 is above the median of 37 across 76 interventional studies indexed under Carcinoma, Adenoid Cystic.

Browse Carcinoma, Adenoid Cystic studies →

Lead sponsor

CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven primary head and neck ACC;
  • Unresectable stage or residual macroscopic disease after surgery or multiple microscopic margins after surgery;
  • Patient with resectable tumor but refusing surgery
  • cN0/pN0 - cN1/pN1 patients (only ipsilateral neck levels I and II)
  • Absence of distant or oligometastatic status (patients with ≤ 3 metastatic lung or bone lesions, excluding other sites;
  • No previous radiotherapy in head and neck region;
  • Performance Status ≥ 70;
  • Age ≥ 18 years;
  • Written
  • Patients' ability to understand the characteristics and consequences of the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Local conditions contraindicating CIRT (e.g., active infection or previous history of recurrent infections in or close to the tumor site; intratumoral necrosis in strict proximity of vessels; pre-existing skin, bone or soft tissue fistula; extended mucosal involvement by the tumor; previous surgery with flap reconstruction);
  • Tumour site in nasopharynx, pharynx and tongue base (where an exclusive CIRT treatment could be at high risk of toxicity);
  • Tumor disease involving ≥ 50% of the palate with consequent high risks of serious anatomical damage in case of significant and rapid disease response to CIRT
  • Nodal involvement > cN1/pN1 or cN1/pN1 outside ipsilateral levels I and II
  • Tumor surrounding carotid artery > 180° or infiltrating the vessels
  • itanium surgical implants or metal prostheses or any other condition that prevents adequate imaging to identify the target volume and may determine uncertainties in CIRT dose distribution during treatment planning
  • Presence of any comorbidity deemed to impact on treatment toxicity;
  • Psychic or other disorders that may prevent
  • Active disease (e.g. systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis)
  • to MRI
  • Pregnancy or breastfeeding in progress
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    carbon ion radiotherapy

    simultaneous integrated boost with carbon ion radiotherapy

    Radiation: simultaneous integrated boost of carbon ions radiation therapy

Interventions

  • Radiationsimultaneous integrated boost of carbon ions radiation therapy

    CIRT Treatment will be delivered in 16 fractions, 4 fractions per week. Treatment plans will be calculated with a Simultaneous Integrated Boost Approach (SIB). The HR-CTV will receive a total dose of 65.6 GyRBE (4.1 GyRBE/fraction). The LR-CTV will simultaneously receive a total dose of 54.4 GyRBE (3.4 GyRBE/fraction) or 48 GyRBE (3 GyRBE/fraction) at discretion of Radiation Oncologist depending on the prognostic factors (54.4 GyRBE in case of macroscopical perineural invasion or positive margin along the nerve, 48.0 Gy(RBE) in case of elective perineural irradiation or microscopic focal intratumor perineural invasion).

    Also known as: CIRT

06

What researchers measure

Primary outcomes

  1. acute and sub acute toxicity as assessed by CTACE 5.0

    Acute and subacute toxicity will be assessed with clinical evaluation within 180 days after the end of treatment and graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: 90 and 180 days after radiation treatment

Secondary outcomes

  1. local control assessed through head and neck MRI

    LC is expected to be the same as in the sequential traditional approach

    Time frame: from last day of radiation treatment up to 12 months until disease progression or death or last follow up up to 5 years

  2. toxicity evaluation

    various toxicity endpoints will be aggregated and analysed to build predictive factors to build multivariate predictive models

    Time frame: toxicity assessed at 90, 120, 180 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Feb 2026, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2023
First posted
Feb 17, 2023
StartActual
Nov 28, 2023
Primary completionEst.
Feb 27, 2026
CompletionEst.
Nov 28, 2026
Last update
Feb 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05733910
Lead sponsor
CNAO National Center of Oncological Hadrontherapy
Responsible party
Sponsor
First posted
Feb 17, 2023
Start date
Nov 28, 2023
Primary completion
Feb 27, 2026 (estimated)
Completion
Nov 28, 2026 (estimated)
Last update
Feb 13, 2025

Study contacts

Sara Ronchi, MD
Contact
sara.ronchi@cnao.it
+390382078501
Cristina Bono, MSc
Contact
cristina.bono@cnao.it
0382078613
Sara Ronchi, MD
principal investigator · CNAO National Center of Oncological Hadrontherapy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion